Astria Therapeutics Announces Board Changes and Shareholder Votes
| Field | Detail |
|---|---|
| Company | Astria Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, governance, shareholder-vote
TL;DR
Astria Therapeutics board shakeup: Leiden out, Michaels in. Shareholder votes coming up.
AI Summary
Astria Therapeutics, Inc. announced on June 11, 2025, the departure of Director Dr. Jeffrey M. Leiden and the appointment of Dr. Sarah E. Michaels as a new director. The company also reported on compensatory arrangements for certain officers and the submission of matters to a vote of security holders.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while shareholder votes directly impact corporate decisions.
Risk Assessment
Risk Level: medium — Board changes and upcoming shareholder votes introduce a degree of uncertainty regarding future company direction and decision-making.
Key Players & Entities
- Astria Therapeutics, Inc. (company) — Registrant
- Dr. Jeffrey M. Leiden (person) — Departing Director
- Dr. Sarah E. Michaels (person) — Appointed Director
- June 11, 2025 (date) — Date of earliest event reported
FAQ
Who has departed from Astria Therapeutics' board of directors?
Dr. Jeffrey M. Leiden has departed from the board of directors.
Who has been appointed as a new director to Astria Therapeutics' board?
Dr. Sarah E. Michaels has been appointed as a new director.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 11, 2025.
What other items are reported in this 8-K filing besides director changes?
The filing also reports on compensatory arrangements of certain officers and the submission of matters to a vote of security holders.
What is the company's primary business as indicated by its SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 by Dr. Jeffrey M. Leiden regarding Astria Therapeutics, Inc..